Biocon said on 18 November that the European Commission has granted marketing authorisation for Pebrilzo, its pertuzumab biosimilar, for HER2-positive breast cancer across multiple disease stages. The announcement adds a regulatory milestone to the company’s oncology portfolio. It does not, by itself, establish a European launch date, selling price or near-term revenue contribution.
The company’s exchange-filed release says Pebrilzo is the first biosimilar to receive European Commission authorisation under the European Medicines Agency’s new tailored clinical approach. That first-under-the-pathway description is Biocon’s statement, rather than an independently established ranking in this report.
What the treatment authorisation covers
Pebrilzo is a biosimilar, not a newly invented cancer-treatment molecule. The EMA product page identifies pertuzumab as its active substance and Perjeta as the reference medicine. It describes comparable quality, safety and efficacy. That distinction matters: the development concerns another biological medicine with high similarity to an existing reference product, not evidence of a new cure.
The filing describes a 420 mg concentrate for solution for infusion. Its stated uses are in specified combinations with other medicines for adults with HER2-positive breast cancer. They include treatment before surgery for certain higher-risk cases, treatment after surgery for higher-risk early disease, and a defined metastatic or locally recurrent setting.
This is not an authorisation for every breast-cancer patient or for standalone use in all settings. The EMA page says treatment should begin under a physician experienced in administering anti-cancer medicines. The news is a company and regulatory development, not personal medical advice.
Keep the company announcement and EMA page separate
Biocon says the Commission’s authorisation follows a positive CHMP opinion dated 17 September 2026 and recent US FDA approval. The EMA page checked for this report still displayed the positive-opinion stage, with wording describing a recommendation for authorisation rather than an updated Commission decision.
Accordingly, this article attributes the new authorisation to Biocon’s 18 November exchange filing. It does not present the EMA page as independent confirmation of that later decision or infer a Commission decision date that the reviewed material does not establish.
Biocon also describes pertuzumab as its fifth oncology biosimilar approved in both Europe and the United States. That portfolio count is a company-reported measure, not a forecast of market share.
The commercial questions remain open
The reviewed release does not set out a country-by-country rollout, pricing, reimbursement timetable, contracted sales or a quantified earnings contribution. Those are the next disclosures to track before translating the regulatory announcement into a financial estimate. Approval and realised sales are different milestones.
Sources: Biocon’s 18 November exchange filing; EMA’s Pebrilzo product page; and PTI’s report in BusinessLine. The lead artwork is an original conceptual illustration, not a photograph of the product or a Biocon facility.
